DDX21-SIRT7-NAT10 Axis Drives mRNA ac4C Modification in CRC Metastasis

Study Background and Research Question

Colorectal cancer (CRC) remains a significant global health burden, ranking as the third most common malignancy and the second leading cause of cancer-related mortality. Despite advances in screening and therapy, prognosis remains poor for many patients, largely due to the high rate of metastasis and the critical role of angiogenesis in tumor dissemination. While DExD/H-box helicases like DDX21 have been implicated in diverse RNA metabolic processes and cancer progression, the precise mechanisms linking DDX21 to CRC metastasis and angiogenesis were previously unclear (Song et al., 2025).

Key Innovation from the Reference Study

The central innovation of this study is the identification of a mechanistic link whereby DDX21, a DExD/H-box RNA helicase, enhances metastatic and angiogenic potential in CRC through modulation of RNA modification. Specifically, DDX21 exerts its effects by competitively binding to SIRT7, thereby inducing NAT10 expression and promoting N4-acetylcytidine (ac4C) modification on mRNAs. This modification increases the stability and expression of genes crucial for metastasis and angiogenesis, namely ATAD2, SOX4, and SNX5 (Song et al., 2025).

Methods and Experimental Design Insights

The authors employed a multifaceted approach to dissect the DDX21/NAT10 axis in CRC:

• Clinical Specimens: CRC tissue microarrays and fresh frozen samples (qRT-PCR validated) were collected from patients who had not received chemoradiotherapy, enabling direct association of DDX21 expression with clinicopathological features.
• Cellular Models: Human CRC cell lines (HCT116, SW620, SW480, DLD-1, LoVo) were used for in vitro gain- and loss-of-function studies, focusing on migration, invasion, and angiogenesis assays.
• Animal Models: In vivo metastasis and angiogenesis were evaluated using xenograft models in immunodeficient mice, allowing the assessment of DDX21's functional role in a physiological context.
• Molecular Assays: Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), and RNA immunoprecipitation (RIP) were used to interrogate protein-protein and protein-RNA interactions. ac4C-RNA immunoprecipitation assessed RNA modification status.
• Gene Expression Analyses: qRT-PCR and western blotting quantified DDX21, NAT10, SIRT7, and target mRNAs/proteins.

This systematic approach enabled precise mapping of the molecular interactions between DDX21, SIRT7, NAT10, and downstream effectors.

Protocol Parameters

• tissue microarray assay | 100-200 samples | clinical correlation in CRC | ensures robust statistical power for biomarker discovery | paper
• qRT-PCR | 20–40 ng total RNA per reaction | gene expression validation | sensitive detection of low-abundance mRNAs | paper
• in vitro migration/invasion assay | 24–48 hours incubation | CRC cell motility analysis | captures real-time effects of gene modulation | paper
• ac4C-RNA immunoprecipitation | 50–200 µg total RNA | RNA modification studies | assesses global and gene-specific ac4C status | paper
• in vivo xenograft assay | 1×10⁶ cells/mouse | metastatic/angiogenic capacity | models physiological relevance | paper
• in vitro transcription enzyme (e.g., T7 RNA Polymerase) | 1–2 µg linearized plasmid template | mRNA probe/preparation | recommended for RNA probe synthesis in similar workflows | workflow_recommendation

Core Findings and Why They Matter

The study demonstrates several key findings:

• DDX21 Overexpression in CRC: DDX21 levels are elevated in CRC tissues and positively correlate with poor prognosis and malignant phenotype (Song et al., 2025).
• Promotion of Metastasis and Angiogenesis: Functional assays reveal that DDX21 enhances metastatic behavior and angiogenesis both in vitro and in vivo.
• Mechanistic Elucidation: DDX21 directly interacts with SIRT7, competitively binding at SIRT7's catalytic domain. This inhibits SIRT7's deacetylation of H3K18, resulting in transcriptional activation of NAT10.
• ac4C Modification Cascade: Upregulated NAT10 catalyzes ac4C modification of target mRNAs (ATAD2, SOX4, SNX5), boosting their stability and expression. These genes are implicated in metastatic and angiogenic signaling.

These findings collectively reveal a robust post-transcriptional regulatory mechanism in CRC progression, highlighting potential intervention points at the DDX21/NAT10 axis.

Comparison with Existing Internal Articles

Several internal resources provide context for the experimental tools and approaches relevant to this study:

• T7 RNA Polymerase: Precision DNA-Dependent RNA Synthesis discusses the use of T7 RNA Polymerase as a benchmark in vitro transcription enzyme for high-fidelity RNA synthesis from linearized plasmid templates. This tool is foundational in generating RNA probes and substrates for assays such as those utilized in ac4C-RNA immunoprecipitation workflows.
• Translational RNA Synthesis: Harnessing T7 RNA Polymerase integrates mechanistic and translational insights, echoing the importance of robust in vitro transcription systems for advanced RNA modification studies and RNA vaccine production.
• T7 RNA Polymerase (SKU K1083): Reliable RNA Synthesis details scenario-driven experimental design, underscoring the value of reproducible RNA synthesis in functional genomics, which is directly applicable to the RNA modification and stability assays highlighted in the reference study.

While these internal articles focus on the technical execution of RNA synthesis and probe preparation, the reference paper extends the conceptual framework by revealing how RNA modifications themselves drive cancer phenotypes, underscoring the interplay between molecular tools and biological discovery.

Limitations and Transferability

The findings, while mechanistically compelling, are subject to certain limitations:

• Clinical Scope: Although the study included a well-characterized cohort of CRC patients, further multi-center validation is needed to generalize the prognostic value of DDX21 and NAT10.
• In Vivo Modeling: The use of immunodeficient mouse models, while informative, does not fully recapitulate the tumor-immune microenvironment present in human CRC.
• Therapeutic Translation: The study lays a foundational rationale for targeting the DDX21/NAT10 axis, but preclinical and clinical development of specific inhibitors or modulators will require further investigation.

Transferability to other cancer types or contexts should be approached cautiously, as the regulatory relationships between DDX21, SIRT7, and NAT10 may be cell-type or tumor-type specific (Song et al., 2025).

Research Support Resources

Researchers aiming to reproduce or expand upon these findings can leverage robust in vitro transcription systems for RNA probe and substrate generation. For example, T7 RNA Polymerase (SKU K1083) from APExBIO, a recombinant enzyme expressed in E. coli, offers high specificity for T7 promoter-driven transcription. This enzyme supports workflows such as ac4C-RNA immunoprecipitation and the synthesis of RNA for antisense RNA and RNAi research, as described in multiple internal guides. Adoption of validated in vitro transcription enzymes ensures experimental fidelity in RNA modification and stability studies (workflow_recommendation).